Bullish Case: Helium's +6.1% forecast, Novartis' $50M MRT-6160 Phase 2 Sjögren's milestone, Wedbush's $27 target, and validated molecular-glue momentum (Revolution's FDA approval) support upside. Helium's density peaks near $12.5–15, and mid-term IV compression (Dec/Jan Helium IV ~10–12% vs market ~95–110%) implies the market overprices tails while pipeline catalysts could drive a sharp repricing higher.

Bearish Case: Put volume exceeding calls by ~130x, backwardated term structure, and deep-OTM put IVs near 400–500% signal concentrated crash/dilution risk. Market density holds meaningful mass below $10, the historical return surface retains severe left tails (-30%+), and prior Helium catalyst calls were repeatedly early with weak realized correlation (0.1). A secondary offering or negative readout could gap the stock hard through thin option liquidity.

Potential Outcomes:

1. 35% No-news drift: price $11.5–14, Helium IV stays below market; falsifiable via no 8-K by mid-October and IV curve flattening.
2. 20% Positive MRT-8102/6160 2H26 update: +20–35%, IV crush; falsifiable via press release/8-K.
3. 18% Secondary/S-3 financing: -15–25%; falsifiable via SEC filing.
4. 10% Safety/efficacy setback: -30%+; falsifiable via trial halt.
5. 7% Deal/M&A: +40–60% binary.
6. 10% Market/liquidity shock (SPY IV >25): -10–20% gap.

September 22, 2026